TABLE OF CONTENTS

3 Introduction of Company

4 R & D

5-6 BIFIDO History

7-8 Our Partners

9 Probiotics Strains List

10-11 Our Research

12 Introduction to B. bifidum BGN4 & B. longum BORI

13-15 BGN4 Abstracts of Literatures

- Effect of probiotic mix(Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo controlled trial.

- Effect of probiotics on Symptoms in Korean Adults with Irritable Syndrome.

- Effect of Bifidobacterium-fermented Soy Hypocotyls Intake on the Composition of Human Large Intestinal Bacteria in the Elderly.

1P

TABLE OF CONTENTS

16-17 BORI Abstracts of Literatures

20-26 BIFIDO Product

27-28 One-Stop Service / Automatic Production Line

18 Patents

19 Our Advantage

29 Stress-Free Tech

30 Global OEM/ODM Service

- The Efficacy of Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 Probiotic Treatment in Infants with Rotavirus Infection.

- Characterization of a Bifidobacterium longum BORI Dipeptidase Belonging to the U34 Family.

- Product Type

- Probiotics Product (Human Probiotics, Oral Probiotics, Pet probiotics)

- Cosmetics Product

2P

IntroductionBIFIDO Co., Ltd. was founded in 1999. In a spirit of challenge to the best technology of Biotech, BIFIDO tries to be the best in the field of microbiome. Of the various probiotics, Bifidobacterium is considered to be the most beneficial microorganism to maintain microbial balance in the intestines. BIFIDO has focused on research and development of Bifidobacterium spp. since 1999. Over 150 of research papers, 40 patents and an INNO-BIZ certificate prove BIFIDO is the top-tier company with greatest experience and expertise in probiotics industry.Recently, BIFIDO started to microbiome research on Rheumatoid arthritis(RA), a chronic inflammatory disease. We analyzed the microbiota of RA patients and tried to find a way to treat even those who were less responsive to treatment. We reveals a novel Bifidobacterium strain as one of the way to overcome severe RA and we expect a new pharmabiotics.BIFIDO Research Center was founded to find new health promoting probiotics and functional ingredients, which are applied to probiotics for human, pet, oral health and cosmetics development. BIFIDO Research Center is working with various research networks including Prof. Geun Eog Ji’s laboratory at Seoul National University and other research teams. BIFIDO has formed strong professional and market advantages in the gut and immune health. We produce raw materials of various probiotics and fermented ginseng by our own technology, our main business is production and sales of own brand ‘ZIGUNUK’, technical support, OEM/ODM. Based on researching and concentrating in the area of intestinal microorganisms and Bifidobacteria over 30 years, we has firmly established our business in probiotics health food and pharmabiotics area.

3P

Research and Development SystemBIFIDO R&D was established to find new health promoting probiotics and functional food materials. BIFIDO applies these research results to functional food and drug development. BIFIDO R&D is working with various research networks including Prof. Geun Eog Ji’s Lab. at Seoul National University and other research teams.

Basic research

Applied research

Industrialization/Production

Seoul National UniversityProf. Geun Eog Ji’s Lab

BIFIDO R&D Center

BIFIDOFactory

- Exploring the functionality of candidate functional substances including probiotics

- Experiment design and evaluation of functional substances - Further research functionality and safety of materials to apply to industry - Market survey and development of marketing strategy

- Scale-up for mass production- Product development- Quality control and Quality assurance- Main products: · Probiotics(raw ingredient & finished product) · Fermented ginseng ACTIVE G5(powder & liquid form) · Nutraceuticals with enhanced activity · Probiotics starter culture · Bifidobacterium expression system

4P

BIFIDO Story

was openedThe first factory

1988

1999.10

2001.06 2003.03

2003.031988-current

Bifidus has been researched by Prof. Ji

was established (Seoul)BIFIDO Co., Ltd.

was introduced to the market for Probiotics research

from the Korean government

Designated asNational Research Labortory

‘Zigunuk Bifidus’

2002.12

was introduced to the market‘Zigunuk Bifidus Baby’We have researched

bifidus for 30 years

1988-2003

5P

BIFIDO Story

2017.05Microbiome research funded by the Korean government

2018.03Introduction of automatic production line

2018.04Microbiome conference 2018

2018.06IHMC conference 2018

2018.01Patent application of a new strain for RA

2017.12Prof. Ji awarded President's Prize for export contribution

2006.03

2011.08

Factory acquired KGMP from the Korean FDA

2011.08Shanghai Branchin China was opened

2015.03

2016.05

Halal certificate(B. bifidum BGN4,B. longum BORI, B. lactis AD011,L. acidophilus AD031, L. casei IBS041)

Halal certificate(Dr.G synbiotics)

Halal certificate2013.03Factory expansion

(L. acidophilus, L. paracasei, L. casei, L. fermentum, L. plantarum)

1988-2003 2006-2018

6P

Global Partners

BIFIDO(Republic of Korea)

7P

Global Partners

8P

Probiotics Strains List

Bifidobacterium spp.

Bifidobacterium bifidum BGN4

Bifidobacterium longum BORI

Bifidobacterium lactis AD011 Lactococcus lactis BH10 Streptococcus thermophilus BH05

Bifidobacterium breve BH12

Bifidobacterium infantis BH07

Lactobacillus acidophilus AD031Lactobacillus casei IBS041

Lactobacillus bulgaricus BH04Lactobacillus helveticus BH14

Lactobacillus fermentum BH03Lactobacillus paracasei BH08

Enterococcus faecium BH06

Enterococcus faecalis BH16Lactobacillus plantarum BH02

Lactobacillus reuteri BH11Lactobacillus rhamnosus BH09Lactobacillus salivarius BH15

Lactobacillus spp. Lactococcus sp. Enterococcus spp. Streptococcus sp.

ARV (Rota-virus)

PAI (Atopic Dermatitis) GNL (IBS)

B. bifidum BGN4 B. longum BORI

B. bifidum BGN4

B. bifidum BGN4B. longum BORI L. paracasei CH88L. acidophilus AD031

B. lactis AD011 L. acidophilus AD031 B. bifidum BGN4 B. lactis AD011 L. acidophilus AD031 L. casei IBS041

Main strains

Genus species

Genus species strain

9P

Our Research Now

Reference: Fig 5. Microbiome–innate-immune-system interactions are involved in multifactorial diseases.The microbiome and innate immunity / Christoph A. Thaiss, Niv Zmora, Maayan Levy & Eran Elinav / Nature. 2016 7;535(7610):65-74.

Rheumatoid arthritisAnkylosing spondtlitis

Pulmonary diseaseand atopy

Inflammatorybowel disease

Type 1 diabetes

Non-alcoholicfatty liver disease

Carcinogenesis

Obesity

Diet

Innateimmune systemMicrobiota

Atherosclerosis

Why does Microbiome balance matter?

10P

Our Research Now

Metabolic disease + Rheumatoid arthritis

Automimmunity

Microbiome profiling of Rheumatoid Arthritis(RA) patients with different therapeutic agents reveals a novel Bifidobacterium strain as one of the way to overcome severe RA.

It is necessary to make a treatment plan by adjusting the Th17/Treg

STAT3 targetingA NEW Paradigm for immune modulation Anti-inflammation

Tissue protectionInflammation

Tissue damage

Treg Th17STAT3inhibitor

Tolerance Autoimmunity

Immune Homeostasis

The Treg / Th17Cell BalanceSTAT5 STAT3

Infection or inflam-mation

Diet Xenobiotics

Healthy microbiota

Bacterial metabolites and

toxins(TMAO, 4-EPS, SCFAs, bile acids and AHR

ligands)

Dysbiosis

Hygiene Genetics

Brain Lung Adipose tissueLiver Intestine Systemic

diseases

Stress

AutismNAFLD

NASH

Obesity

Metabolic disease

Type 1 diabetes

Atheroscle-rosis

Rheumatoid arthritis

IBD

Coeliac disease

Multiple sclerosis

Asthma

Subjectsrecruiting

vs

Controlgroup

Patientsgroup

Stool sampling/gDNA extraction

16S rRNAsequencing

Microbiome profiling

Subjects grouping with various

therapeutic agents

11P

What is B. bifidum BGN4, B. longum BORI?

- Prevention of allergy

- Inhibit IBS

- Anti-tumor

- High adhesion ability

B. bifidum BGN4

- Suppression of pathogens

- Inhibit constipation

- Anti-rotavirus

- Inhibit diarrhea

B. longum BORI

12P

PapersHuman study: Effect on prevalence of atopic dermatitis

Controversy exists regarding the preventive effect of probiotics on the development of eczema or atopic dermatitis. We investigated whether supplementation of probiotics prevents the development of eczema in infants at high risk. In a randomized, double-blind, placebo-controlled trial, 112 pregnant women with a family history of allergic diseases received a once-daily supplement, either a mixture of Bifidobacterium bifidum BGN4, B. lactis AD011, and Lactobacillus acidophilus AD031, or placebo, starting at 4-8 wks before delivery and continuing until 6 months after delivery.Infants were exclusively breast-fed during the first 3 months, and were subsequently fed with breast milk or cow's milk formula from 4 to 6 months of age. Clinical symptoms of the infants were monitored until 1 yr of age, when the total and specific IgE against common food allergens were measured. A total of 68 infants completed the study. The prevalence of eczema at 1 yr in the probiotic group was significantly lower than in the placebo group (18.2% vs. 40.0%, p=0.048). The cumulative incidence of eczema during the first 12 months was reduced significantly in probiotic group (36.4% vs. 62.9%, p=0.029); however, there was no difference in serum total IgE level or the sensitization against food allergens between the two groups. Prenatal and postnatal supplementation with a mixture of B. bifidum BGN4, B. lactis AD011, and L. acidophilus AD031 is an effectiveapproach in preventing the development of eczema in infants at high risk of allergy during the first year of life.

Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial.

Bifidobacterium bifidum BGN4 / Bifidobacterium lactis AD011 / Lactobacillus acidophilus AD031

1Department of Food and Nutrition, College of Human Ecology, Seoul National University, San 56-1, Shinlimdong, Kwanakku, Seoul, Korea2Departmentof Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Cheoncheondong, Jangangu, Suwon, Gyeonggido, Korea 3Department of Pediatrics, Samsung MedicalCenter, 50 Irwon-dong, Gangnam-gu, Seoul, Korea4Department of Pediatrics, Ajou University School of Medicine, San 5, Woncheondong, Youngtonggu, Suwon, Gyeonggido, Korea5Research Institute, Bifido Inc. 688-1, Hongcheongun, Kangwondo, Korea* They contributed to correspondence authors equally to this work.

Ji Yeun Kim1, Jung Hyun Kwon2, So Hyun Ahn2, Sang Il Lee2, Young Shin Han3, Young Ok Choi1, Soo Young Lee4, Kang Mo Ahn2* and Geun Eog Ji1,5*

SYMPTOMS AND IMMUNIZATIONS IN CHILDREN

13P

PapersHuman study: Effects on irritable bowel syndrome

Background/Aims: Irritable bowel syndrome (IBS) is a troublesome disease. Some strains of probiotics reportedly exert remarkable immunomod-ulatory effects, and so we designed a prospective double-blind randomized placebo-controlled clinical study to assess their effects in Korean adults with IBS.

Methods: IBS patients who met Rome III criteria were randomly assigned to receive composite probiotics or placebo. A total of 20 billion lyophilized bacteria were administered twice daily for 8 weeks. Primary outcome variables were symptom scores consisting of abdominal pain, flatulence, defecation discomfort, and sum of symptom scores. A visual analogue scale was used to quantify the severity. Secondary outcome variables consisted of the quality of life and bowel habits including defecation frequency and stool form.

Results: Thirty-six and 34 patients were randomized to the probiotics and placebo groups, respectively. Intention-to-treat analysis showed significant reductions in pain after 8 weeks of treatment: -31.9 and -17.7 in the probiotics and placebo groups, respectively (p=0.045). The reductions in abdominal pain, defecation discomfort, and sum of scores were more significant in 58 patients with a score of at least 3 on the baseline stool-form scale.

Conclusions: Composite probiotics containing Bifidobacterium bifidum BGN4, Lactobacillus acidophilus AD031, and other species are safe and effective, especially in patients who excrete normal or loose stools.

Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome

*Department of Internal Medicine, Seoul National University College of Medicine, †Department of Food and Nutrition, Research Institute of Human Ecology, Seoul National University College of Human Ecology, Seoul, ‡Research Institute, BIFIDO Co., Ltd., Hongchun, Korea

Kyoung Sup Hong*, Hyoun Woo Kang*, Jong Pil Im*, Geun Eog Ji†, ‡, Sang Gyun Kim*, Hyun Chae Jung*, In Sung Song*, and Joo Sung Kim*

Bifidobacterium bifidum BGN4 / Bifidobacterium lactis AD011Lactobacillus acidophilus AD031 / Lactobacillus casei IBS041

14P

PapersHuman study: The binding and growth of probiotics in the intestinal tract

Effect of dietary supplementation of Bifidobacterium-fermented soy hypocotyls (BFSH) on the composition of large intestinal bacteria of the elderly people was investigated. Four grams of BFSH containing 109cfu/g. Bifidobacterium were administered daily to 14 elderly volunteers every day for 10 days, followed by 10 days of non-intake period, and the cycle was repeated for 50 days. Composition of the intestinal bacteria (Bacteroides, Bifidobacterium, Lactobacillus, E. coli, Clostridium perfringens) examined revealed that administration of BFSH resulted in a marked increase in Bifidobacterium and a decrease in Bacteroides. Stool evacuation frequencies, pH, and water contents of the fecal samples did not change significantly.

Effect of Bifidobacterium-fermented Soy Hypocotyls Intake on the Composition of Human Large Intestinal Bacteria in the Elderly

*Administration of B. bifidum BGN4 resulted in 10 times of total Bifidobacterium number increase in large intestine.

Bifidobacterium bifidum BGN4

Department of Food and Nutrition, Seoul National University, Seoul 151-742, Korea 1Research Center, Bifido Inc., Seoul 151-742, Korea Corresponding author: Department of Food and Nutrition, Seoul National University, Seoul 151-742, Korea

Effect of Bifidus intake on the composition of human feces

Beforeintake

Firstintake

Firstnon-intake

Secondnon-intake

Secondintake

15P

Human study: The binding and growth of probioticsin the intestinal tract

PapersWhat are the benefits of probiotics for infants?

Bifidobacterium longum BORI

Abstract: A total of 57 infants hospitalized with rotavirus disease were included in this study. The children were randomly divided into the study’s two treatment groups: three days of the oral administration of (i) a probiotics formula containing both Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 (N = 28); or (ii) a placebo (probiotic-free skim milk, N = 29) and the standard therapy for diarrhea. There were no differences in age, sex, or blood characteristics between the two groups. When the 57 cases completed the protocol, the duration of the patients’ diarrhea was significantly shorter in the probiotics group (4.38±1.29, N = 28) than the placebo group (5.61±1.23, N =29),with a p-value of 0.001. Symptoms such as duration of fever (p=0.119),frequency of diarrhea (p= 0.119), and frequency of vomiting (p= 0.331) tended to be ameliorated by the probiotic treatment; however, differences were not statistically significant between the two groups. There were no serious, adverse events and no differences in the frequency of adverse events in both groups.

Myeong Soo Park 1, Bin Kwon 2, Seock Mo Ku 3 and Geun Eog Ji 2,4,* 1 Department of Hotel Culinary Arts, Yeonsung University, Anyang 430-749, Korea; mspark@yeonsung.ac.kr 2 Research Center, BIFIDO Co. Ltd., Hongcheon 250-804, Korea; 531083@hanmail.net 3 FermentationScienceProgram,SchoolofAgribusinessandAgriscience,CollegeofBasicandAppliedSciences, MiddleTennesseeStateUniversity,Murfreesboro,TN37132,USA;Seockmo.Ku@mtsu.edu 4 Department of Food and Nutrition, Research Institute of Human Ecology, Seoul National University, Seoul 151-742, Korea * Correspondence: geji@snu.ac.kr; Tel.: +82-2-880-6282

16P

Papers

Bifidobacterium longum BORI

Characterization of a Bifidobacterium longum BORI Dipeptidase Belonging to the U34 Family.

Applied and Environmental Microbiology , 2007, 73(17);5598-5606

A dipeptidase was purified from a cell extract of Bifidobacterium longum BORI by ammonium sulfate precip-itation and chromatography on DEAE-cellulose and Q-Sepharose columns. The purified dipeptidase had a molecular mass of about 49 kDa and was optimally active at pH 8.0 and 50°C. The enzyme was a strict dipeptidase, being capable of hydrolyzing a range of dipeptides but not tri- and tetrapeptides, p-nitroan-ilide derivatives of amino acids, or N- or C-terminus-blocked dipeptides. A search of the amino acid sequence of an internal tryptic fragment against protein sequences deduced from the total genome sequence of B. longum NCC2705 revealed that it was identical to an internal sequence of the dipeptidase gene (pepD), which comprised 1,602 nucleotides encoding 533 amino acids with a molecular mass of 60 kDa, and thereby differed considerably from the 49-kDa mass of the purified dipeptidase. To understand this discrepancy, pepD was cloned into an Escherichia coli expression vector (pBAD-TOPO derivative) to generate the recombinant plasmids pBAD-pepD and pBAD-pepD-His (note that His in the plasmid desig-nation stands for a polyhistidine coding region). Both plasmids were successfully expressed in E. coli, and the recombinant protein PepD-His was purified using nickel-chelating affinity chromatography and reconfirmed by internal amino acid sequencing. The PepD sequence was highly homologous to those of the U34 family of peptidases, suggesting that the B. longum BORI dipeptidase is a type of cysteine-type N-terminal nucleophile hydrolase and has a beta-hairpin motif similar to that of penicillin V acylase,which is activated by autoproteolytic processing.

17P

Patents

Department of Food and Nutrition, Seoul National University, Seoul 151-742, Korea 1Research Center, Bifido Inc., Seoul 151-742, Korea Corresponding author: Department of Food and Nutrition, Seoul National University, Seoul 151-742, Korea

Bifidobacterium lactis producing β- glucosidase andmethod for converting isoflavon into isoflavon agluconusing the same

Bifidobacterium longum AR81 enabling inhibition ofrotavirus and active protein separated therefrom

A new anti0candr polysaccharide from the genus Bifidobacterium

Composition for Prevention and Treatment of FoodAllergy containing Bifidobacterium bifidum BGN4 asActive Ingredient

Method of Producing Ginsenoside Rh1

Method of Producing Active Ginsenoside from Ginseng

Anti-angiogenic composition comprising bioconversion materials of Angelica gigas and Zizyphus jujuba water extracts transformed by Aspergillus usamii var. shirousamii

Composition for inhibition against glucose level increase in blood containing fermented or enzyme-treated Rubus coreanus Miquel

Method for continuous production of ginsenoside compound K using immobilized beta-glycosidase

Food composition against allergic rhinitis containing red ginseng liquid fermented

Bifidobacterium animalis BF8 (KFCC11506P) against pathogenic Enterobacter(Cronobacter) sakazakii and food composition therefrom

Method for production of Platycodon radix fermented liquor with bioconverted saponin

Screening method of strain not to produce aflatoxin and cyclopiazonic acid free soybean paste therefrom

Screening method of strain not to produce ochratoxin and fumonisin and mycotoxin free soybean paste therefrom

Remote control system and control sever for microbial incubator, remote control mehtod for microbial incubator, and computer readable recoding medium

PatentsNo.

1

2

3

4

5

6

9

10

11

12

13

14

15

7

8

18P

Our Advantage

Human-OriginBifidus

3 Step Packing System

Study / Culturing of Probiotics

Production

Shipment

Stress-Free Tech

30 years research on beneficial microorganism

in the intestines

Over one hundred of SCI papers related

to probioticsThe largest facility raw materials

company in KoreaPatented strains derived from

human intestine

Human-Origin probiotics are exported to 25 countries and

regions all over the world

3 Step Packing System helps maintain shelf life

Strees-Free Tech helps probiotics' stability, efficacy, and activity

A large number of clinical studies and patents

19P

BIFIDO Product

Probiotics forHuman (Gut/ Oral)

Probiotics for Pet

Powder Sachet Tablet Capsule

Probiotics for Beauty

Product Type

Product Form

20P

Human Probiotics

Instruction for use

ZIGUNUK BIFIDUS PREMIUM

Should use for

Take one stick per day with water or other liquid.

People with constipationPeople with gastrointestinal disordersPeople often eat fast food, soft drinksPeople with over work and stress

- A functional food (Probiotics product)

- 60g(2g x 30 sachets)

- Bifidobacterium bifidum BGN4

- Bifidobacterium longum BORI

- Lactobacillus acidophilus AD031

• Probiotics

• Prebiotics

• Yogurt flavour

• Vitamin C

• Magnesium sterate

• Acacia gum (Dietary fiber > 90%)

- Mixed oligosaccharides(Maltitol, Maltos, Oligopowder)

- Galacto-oligosaccharide

StorageStore the product in a dark, cool place, avoiding high temperature and direct sunlight. It would be better to store the product in the refrigerator to maintain the live probiotics.

Food type and content

Ingredients

This product is for intestinal health of adults, which contains probiotics isolated from Korean intestine such as Bifidobacterium spp. (B. bifidum BGN4, B. longum BORI), and Lactobacillus acidophilus. Fructo- and Galacto-Oligosaccharides are prebiotics to help growth Bifidobacterium sp. It was developed by the research team of Prof. Geun Eog Ji at the Department of Food & Nutrition in Seoul National University.

21P

Human Probiotics

Adult

Gut & Immune health Gut health & Weight management

Baby

(probiotics)

(Probiotics + Vit B complex)

ZIGUNUK BIFIDUS BABY PREMIUM

ZIGUNUK BIFIDUS PREMIUM

Slim yogurtics

(Probiotics + Zn)

(Probiotics + Prebiotics)

ZIGUNUK BIFIDUS Prog

ZIGUNUK BIFIDUS HYO

(Probiotics+Garcinia cambogia)

Replace meal

Bifidus meal

(Probiotics Yogurt )

Senior

Adult & Baby

22P

Oral Probiotics

Bifidus Denti (Stick) Bifidus Denti (Tablet)

Streptococcus mutans decreased by 18.5%

After 4 weeks, Streptococcus mutans decreased 18.5%

Control group increased by 30.0%

OHI-S decreased by 20.7%

The control group, OHI-S decreased by 0.5%

H2S reduced by 48.2%

The control group, H2S decreased by 11.6%

Volatile Sulfur Compounds (VSC) reduced

Oral Hyglene-Index-Simplified (OHI-S)

decreased

23P

Pet Probiotics

Usage

Ingredients

Take one or two stick per day. Mix it with dog food.

Bifidobacterium bifidum BGN4,Bifidobacterium longum BORI,Lactobacillus acidophilus,Lactobacillus casei, Isomaltulose, Maltitol syrup, etc.

Usage

Ingredients

Take one or two stick per day. Mix it with cat food

Bifidobacterium bifidum BGN4,Bifidobacterium longum BORI,Lactobacillus acidophilus,Lactobacillus casei, Isomaltulose, Maltitol, etc.

PETBIOTICS DOG

PETBIOTICS CAT

24P

CosmeticsBIFIDO LAB works for your Skin ?

BIFIDUM- SAPTM

Bifida ferment lysate by B. bifidum BGN4 and B. longum BORI

Lactobacillus ferment lysate by L. paracasei CH88

LACTIC ACID,BACTERIOCIN

(Antimicrobial, Acne Care) PEPTIDOGLYCAN(Moisturizing)

POLYSACCHARIDE(Moisturizing) POLYNUCLEOTIDE

(DNA,RNA;UV Protection,Regeneration)

LACTOCEPIN(Anti-inflammatory,

Acne Care)

Fermented Ginseng

1. Core ingredient

2. Bifidum Bio-Creaking Technology (BBCT TM)

Bifidum-SAP TM

The variety of skin microflora allows you to maintain your skin healthy such as the beneficial microorganisms keep our intestines more functional. BIFIDO LAB studies skin microflora that protects your skin from harmful external environment and toxic chemicals

BBCTTM(that produces BIFIDUM-SAPTM) is the technology that extracts active substances from the patented bacteria cells without added enzymes or chemicals. These physiologically maximized active ingredients in bacteria work more effectively on your skin.

VALVESEAT

IMPACTRING

BASICPRODUCT VALVE

HOMEGENIZEDPRODUCT

25P

CosmeticsBIFIDO LAB works for your Skin ?

Gentle Exfoliating Clenser Gel

Soothing Toner

Cream

This Gentle exfoliating clenser gel goes deep into pores to remove the impurities and dead skin cells with the acitve ingredient in BIFIDUM-SAPTM.

B. bifidum BGN4B. longum BORI

L. paracasei CH88

Polynucleotide(DNA. RNA)

Skin protection(UV-protection, Regeneration)

Antimicrobial(Acne Care)

Hydroscopic(Moisturizing)

Anti-inflammatory(Acne Care)

Bacteriocin/Lactic Acid

Peptidoglycan/Polysaccharide Lactocepin

The active ingredient in the toner provides moisture into your skin rapidly and it makes your skin smoother.

This cream contains the active ingredient and DNA from PROBIOTICS. These protect our skin from the external stimulus such as contaminated particles and maintain better water balance on it.

3. Effectiveness of BIFIDUM-SAP TM on your skin

4. Products

BIFIDUM-SAP TM is the active key material in our products, it contains beneficial ingredients such as DNA,RNA, peptidoglycan, polysaccharide, lactocepin, bacteriocin and lactic acids.

Recently the numerous people are suffering from skin troubles, due to the life pattern changes and surrounding environments. A lot of external factors including the fine dusts, yellow dusts, rapid season changes, and stresses have been weakening skin conditions and collapsing the balance of the microflora on human skin. BIFIDO LAB is the skin care brand that helps the customers who suffer from sensitive skin and want to maintain better skin. We use the verified probiotics ingredients developted by our own technology.

26P

One-Stop Service

Fermenter Concentrator Lyophilizer Crushing Chamber

Icebox Packing

Finished Product(Probiotics Strain)

Mixer

Mixer

Sachet

Final Packing

Liquid PouchTablet Capsule

Box Packing

27P

Automatic Production Line

Production Capability : 1Million sachets/day

Sachet Packing Sachet Transfer Pillow Packing

Box Transfer Box Packing Pillow Transfer

28P

Stress-Free Tech

We are leading the way to improve human health by leading microbiome technology.

Stability / Efficacy / Activity

Stress-Free Tech

Strain isolation

Inoculation

Culture

Seperation

Freeze drying

QC test in raw material

Production finished product

QC test in finished product

Strain storage

Alleren free

29P

Global OEM/ODMOEM (Original Equipment Manufacturing)

ODM (Original Development & Design Manufacturing)

Demandby customer

Consultabout business

Sign a contract

Produce

Deliver

Develop preparations& Decide on

specimen

Demandby customer

Consultabout business

Sign a contract

Produce

Deliver

Develop preparations& Decide on

specimen

Develop design

& Decide on specimen

Sales DeptR & D Dept

Sales Dept

ProductionDeptR & D Dept

Production support

Dept

Planning DeptR & D Dept

Production DeptR & D Dept

Warehouse the raw

materialsand

accessories

30P

Microbiome Leader

Head Office:23-16 Nonggongdanji-gil, Hongcheon-eup, Hongcheon-gun Gangwon-do 25117, Republic of Korea

Seoul Office:639 Seonleung-ro Gangnam-gu, Seoul,Republic of KoreaFax:+82-33-435-4963 / Tel:+82-33-435-4962

Email: bgn4@bifido.com